Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

564 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction.
Fihlman M, Hemmilä T, Hagelberg NM, Kuusniemi K, Backman JT, Laitila J, Laine K, Neuvonen PJ, Olkkola KT, Saari TI. Fihlman M, et al. Among authors: neuvonen pj. Eur J Clin Pharmacol. 2016 Nov;72(11):1363-1371. doi: 10.1007/s00228-016-2109-y. Epub 2016 Aug 10. Eur J Clin Pharmacol. 2016. PMID: 27510521 Clinical Trial.
Rifampicin markedly decreases the exposure to oral and intravenous tramadol.
Saarikoski T, Saari TI, Hagelberg NM, Neuvonen M, Neuvonen PJ, Scheinin M, Olkkola KT, Laine K. Saarikoski T, et al. Among authors: neuvonen pj, neuvonen m. Eur J Clin Pharmacol. 2013 Jun;69(6):1293-301. doi: 10.1007/s00228-012-1460-x. Epub 2012 Dec 15. Eur J Clin Pharmacol. 2013. PMID: 23242004 Clinical Trial.
Ticlopidine inhibits both O-demethylation and renal clearance of tramadol, increasing the exposure to it, but itraconazole has no marked effect on the ticlopidine-tramadol interaction.
Hagelberg NM, Saarikoski T, Saari TI, Neuvonen M, Neuvonen PJ, Turpeinen M, Scheinin M, Laine K, Olkkola KT. Hagelberg NM, et al. Among authors: neuvonen pj, neuvonen m. Eur J Clin Pharmacol. 2013 Apr;69(4):867-75. doi: 10.1007/s00228-012-1433-0. Epub 2012 Oct 26. Eur J Clin Pharmacol. 2013. PMID: 23099620 Clinical Trial.
564 results